CORDIS - Resultados de investigaciones de la UE
CORDIS

Development of novel vaccines to control infections wlth newly emerging highly pathogenic marek's disease viruses

Objetivo

Novel concepts to control newly emerging and highly pathogenic Marek's disease virus (vv+ MDV-1) are needed. Different antigen formulations, routes of vaccination, and biological adjuvant will be tested. DNA vaccines encoding MDV-1 antigens expressed in all stages of the virus' life cycle (lytic, latent, tumour stage) will be constructed, with an emphasis on antigens inducing a cytotoxic T cell response. The same proteins will also be expressed by recombinant Sindbis viruses. Modified live vaccines derived from a vv+ MDV-1 strain with a deletion in gB or gM shall be constructed using the bacterial artificial chromosome technique. The routes of vaccination will be
1) in-ovo vaccination and
2) vaccination of 1- day-old chickens via various routes. The cytokine profiles after MDV-1 infection will be analysed by developing new tools and test systems, and rational approaches to immune modulation using biological adjuvant will be developed and tested.

Convocatoria de propuestas

Data not available

Régimen de financiación

CSC - Cost-sharing contracts

Coordinador

FRIEDRICH-LOEFLER INSTITUTE FEDERAL RESEARCH INSTITUT FOR ANIMAL HEALTH
Aportación de la UE
Sin datos
Dirección
Boddenblick 5 A
17498 INSEL RIEMS
Alemania

Ver en el mapa

Coste total
Sin datos

Participantes (7)